S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:INVO

INVO Bioscience Stock Forecast, Price & News

$2.94
-0.05 (-1.67%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.77
$3.05
50-Day Range
$2.93
$4.19
52-Week Range
$2.67
$12.30
Volume
27,729 shs
Average Volume
582,546 shs
Market Capitalization
$34.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.99
30 days | 90 days | 365 days | Advanced Chart
Receive INVO News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.


INVO Bioscience logo

About INVO Bioscience

INVO BioScience, Inc. focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.

Headlines

INVO Bioscience (NASDAQ:INVO) Issues Earnings Results
November 16, 2021 |  americanbankingnews.com
Here's what to expect from INVO Bioscience's earnings
November 14, 2021 |  markets.businessinsider.com
INVO Bioscience (INVO) Set to Announce Quarterly Earnings on Monday
November 11, 2021 |  americanbankingnews.com
INVO Bioscience (NASDAQ:INVO) Stock Price Down 1.5%
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INVO
Fax
N/A
Employees
10
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.04 million
Book Value
$0.20 per share

Profitability

Net Income
$-8.35 million
Net Margins
-787.94%
Pretax Margin
-806.03%

Debt

Price-To-Earnings

Miscellaneous

Free Float
10,841,000
Market Cap
$34.50 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/29/2022

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

899th out of 1,391 stocks

Surgical & Medical Instruments Industry

96th out of 125 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












INVO Bioscience (NASDAQ:INVO) Frequently Asked Questions

Is INVO Bioscience a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INVO Bioscience in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INVO Bioscience stock.
View analyst ratings for INVO Bioscience
or view top-rated stocks.

Are investors shorting INVO Bioscience?

INVO Bioscience saw a increase in short interest in October. As of October 29th, there was short interest totaling 122,500 shares, an increase of 29.6% from the October 14th total of 94,500 shares. Based on an average daily trading volume, of 46,100 shares, the days-to-cover ratio is presently 2.7 days.
View INVO Bioscience's Short Interest
.

When is INVO Bioscience's next earnings date?

INVO Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for INVO Bioscience
.

How were INVO Bioscience's earnings last quarter?

INVO Bioscience, Inc. (NASDAQ:INVO) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. INVO Bioscience had a negative trailing twelve-month return on equity of 228.66% and a negative net margin of 787.94%. During the same period last year, the firm earned ($0.36) EPS.
View INVO Bioscience's earnings history
.

What price target have analysts set for INVO?

2 Wall Street analysts have issued 1 year price objectives for INVO Bioscience's stock. Their forecasts range from $5.25 to $5.25. On average, they expect INVO Bioscience's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price.
View analysts' price targets for INVO Bioscience
or view top-rated stocks among Wall Street analysts.

Who are INVO Bioscience's key executives?

INVO Bioscience's management team includes the following people:
  • Steven M. Shum, Chief Executive Officer & Director
  • Michael J. Campbell, Chief Operating Officer & VP-Business Development
  • Andrea Goren, Chief Financial Officer
  • Kevin Doody, Director & Medical Director
  • Inger Britt Carlsson, Vice President-Medical Affairs

What is INVO Bioscience's stock symbol?

INVO Bioscience trades on the NASDAQ under the ticker symbol "INVO."

How do I buy shares of INVO Bioscience?

Shares of INVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is INVO Bioscience's stock price today?

One share of INVO stock can currently be purchased for approximately $2.94.

How much money does INVO Bioscience make?

INVO Bioscience has a market capitalization of $34.50 million and generates $1.04 million in revenue each year. The company earns $-8.35 million in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does INVO Bioscience have?

INVO Bioscience employs 10 workers across the globe.

What is INVO Bioscience's official website?

The official website for INVO Bioscience is www.invobioscience.com.

Where are INVO Bioscience's headquarters?

INVO Bioscience is headquartered at 5582 BROADCAST COURT, SARASOTA FL, 34240.

How can I contact INVO Bioscience?

INVO Bioscience's mailing address is 5582 BROADCAST COURT, SARASOTA FL, 34240. The company can be reached via phone at (978) 878-9505 or via email at [email protected].


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.